These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 29171770)

  • 1. Emerging biomarkers of lymphangioleiomyomatosis.
    Nijmeh J; El-Chemaly S; Henske EP
    Expert Rev Respir Med; 2018 Feb; 12(2):95-102. PubMed ID: 29171770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells.
    Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP
    Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [
    Verwer EE; Kavanagh TR; Mischler WJ; Feng Y; Takahashi K; Wang S; Shoup TM; Neelamegam R; Yang J; Guehl NJ; Ran C; Massefski W; Cui Y; El-Chemaly S; Sadow PM; Oldham WM; Kijewski MF; El Fakhri G; Normandin MD; Priolo C
    Clin Cancer Res; 2018 Dec; 24(23):5925-5938. PubMed ID: 30054282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases.
    Young LR; Vandyke R; Gulleman PM; Inoue Y; Brown KK; Schmidt LS; Linehan WM; Hajjar F; Kinder BW; Trapnell BC; Bissler JJ; Franz DN; McCormack FX
    Chest; 2010 Sep; 138(3):674-81. PubMed ID: 20382711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis.
    Hirose M; Matsumuro A; Arai T; Sugimoto C; Akira M; Kitaichi M; Young LR; McCormack FX; Inoue Y
    PLoS One; 2019; 14(2):e0212776. PubMed ID: 30818375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of serum vascular endothelial growth factor-D in Korean patients with lymphangioleiomyomatosis.
    Yoon HY; Moon SJ; Kim SY; Park JS; Choi SM; Kang HK; Song JW
    Ther Adv Respir Dis; 2024; 18():17534666241272928. PubMed ID: 39148439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lymphangioleiomyomatosis - new concepts on pathogenesis, diagnosis and treatment].
    Sobiecka M
    Wiad Lek; 2016; 69(2 Pt 1):123-9. PubMed ID: 27421126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
    Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
    PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center.
    Amaral AF; de Oliveira MR; Dias OM; Arimura FE; Freitas CSG; Acencio MMP; de Alvarenga VA; Kairalla RA; Carvalho CRR; Baldi BG;
    Lung; 2019 Apr; 197(2):139-146. PubMed ID: 30623243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis.
    Radzikowska E; Jaguś P; Sobiecka M; Chorostowska-Wynimko J; Wiatr E; Kuś J; Roszkowski-Śliż K
    Respir Med; 2015 Nov; 109(11):1469-75. PubMed ID: 26386638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
    Mou Y; Ye L; Wang J; Yee MS; Song YL; Zhu L; Jin ML
    Lymphology; 2016 Sep; 49(3):140-9. PubMed ID: 29906075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses.
    Hayashi T; Kumasaka T; Mitani K; Okada Y; Kondo T; Date H; Chen F; Oto T; Miyoshi S; Shiraishi T; Iwasaki A; Hara K; Saito T; Ando K; Kobayashi E; Gunji-Niitsu Y; Kunogi M; Takahashi K; Yao T; Seyama K
    Hum Pathol; 2016 Apr; 50():34-42. PubMed ID: 26997436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM).
    Xu KF; Zhang P; Tian X; Ma A; Li X; Zhou J; Zeng N; Gui YS; Guo Z; Feng R; Zhang W; Sun W; Cai B
    Respir Med; 2013 Feb; 107(2):263-8. PubMed ID: 23127572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis.
    Atochina-Vasserman EN; Abramova E; James ML; Rue R; Liu AY; Ersumo NT; Guo CJ; Gow AJ; Krymskaya VP
    Am J Physiol Lung Cell Mol Physiol; 2015 Dec; 309(12):L1447-54. PubMed ID: 26432869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mast-Cell Tryptase Release Contributes to Disease Progression in Lymphangioleiomyomatosis.
    Babaei-Jadidi R; Dongre A; Miller S; Castellanos Uribe M; Stewart ID; Thompson ZM; Nateri AS; Bradding P; May ST; Clements D; Johnson SR
    Am J Respir Crit Care Med; 2021 Aug; 204(4):431-444. PubMed ID: 33882264
    [No Abstract]   [Full Text] [Related]  

  • 16. Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet.
    Gibbons E; Minor BMN; Hammes SR
    Endocr Relat Cancer; 2023 Sep; 30(9):. PubMed ID: 37410387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sporadic Lymphangioleiomyomatosis (sLAM) and Tuberous Sclerosis Complex (TSC) - Pulmonary Manifestations].
    Brakemeier S; Grohé C; Bachmann F; Budde K
    Pneumologie; 2017 Feb; 71(2):86-95. PubMed ID: 27585353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In situ analysis of mTORC1/2 and cellular metabolism-related proteins in human Lymphangioleiomyomatosis.
    Krencz I; Sebestyen A; Papay J; Jeney A; Hujber Z; Burger CD; Keller CA; Khoor A
    Hum Pathol; 2018 Sep; 79():199-207. PubMed ID: 29885404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphangioleiomyomatosis: a metastatic lung disease.
    Kundu N; Holz MK
    Am J Physiol Cell Physiol; 2023 Feb; 324(2):C320-C326. PubMed ID: 36571446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis: Progress and Future Directions.
    Liu HJ; Krymskaya VP; Henske EP
    Chest; 2019 Dec; 156(6):1062-1067. PubMed ID: 31437431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.